MedWatch

Ascendis Pharma aims for USD 400m from share issue

A week after Ascendis Pharma received approval for its once-weekly growth hormone treatment, the biotech company has started to look for capital.

Photo: Kevin Grønnemann/MedWatch

Ascendis Pharma wants to bulk up its economic muscles and has therefore started an equity issuance the company hopes can bring in USD 400m (DKK 2.5bn) to the firm.

This comes shortly after the biotech company received approval for its once-weekly growth hormone, Transcon hGH, from the US Food and Drug Administration.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs